Related Experiment Video
Updated: May 19, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial
Christoph Grimm1, Stephan Polterauer, Camilla Natter
1Department of General Gynaecology and Gynaecological Oncology, Comprehensive Cancer Center, the Center for Medical Statistics, Informatics and Intelligent Systems, Section for Clinical Biometrics, and the Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, and the Karl Landsteiner Institute for Gynecologic Surgery and Oncology, Vienna, Austria. christoph.grimm@meduniwien.ac.at
Insights
Topical imiquimod effectively treats high-grade cervical intraepithelial neoplasia (CIN 2-3), showing significant regression and remission rates. This immune-modulating therapy offers a promising alternative to surgery for CIN 2-3.
Area of Science:
- Gynecology
- Oncology
- Immunology
Background:
- High-grade cervical intraepithelial neoplasia (CIN 2-3) requires effective treatment alternatives to surgery.
- Imiquimod, a topical immune-response modulator, presents a potential therapeutic option.
Purpose of the Study:
- To evaluate the efficacy of topical imiquimod in treating CIN 2-3.
- To assess imiquimod's impact on histologic regression, complete remission, and human papillomavirus (HPV) clearance.
Main Methods:
- A randomized trial involving 59 patients with untreated CIN 2-3.
- 16-week self-applied vaginal suppository treatment with either imiquimod or placebo.
- Primary outcome: histologic regression to CIN 1 or less; secondary outcomes: complete remission, HPV clearance, and tolerability.
Main Results:
- 73% regression in the imiquimod group vs. 39% in placebo (P=.009).
- Complete remission was 47% with imiquimod vs. 14% with placebo (P=.008).
- HPV clearance was 60% with imiquimod vs. 14% with placebo (P<.001).
Conclusions:
- Topical imiquimod demonstrates significant efficacy in treating CIN 2-3.
- The treatment is well-tolerated and feasible, offering a viable alternative to surgical interventions.
Objective:
Alternatives to surgical therapy are needed for the treatment of high-grade cervical intraepithelial neoplasia (CIN 2-3). We aimed to estimate the efficacy of a treatment with imiquimod, a topical immune-response modulator, in patients with CIN 2-3.
Materials And Methods:
Fifty-nine patients with untreated CIN 2-3 were randomly allocated to a 16-week treatment with self-applied vaginal suppositories containing either imiquimod or placebo. The main outcome was efficacy, defined as histologic regression to CIN 1 or less after treatment. Secondary outcomes were complete histologic remission, human papillomavirus (HPV) clearance, and tolerability. Assuming a two-sided 5% significance level and a power of 80%, a sample size of 24 patients per group was calculated to detect a 35% absolute increase in CIN 2-3 regression.
Results:
Histologic regression was observed in 73% of patients in the imiquimod group compared with 39% in the placebo group (P=.009). Complete histologic remission was higher in the imiquimod group (47%) compared with the placebo group (14%) (P=.008). At baseline, all patients tested positive for high-risk HPV. Human papillomavirus clearance rates were increased in the imiquimod group (60%) compared with the placebo group (14%) (P<.001). In patients with HPV-16 infection, complete remission rates were 47% in the imiquimod group compared with 0% in the placebo group (P=.003). Microinvasive cancer was observed in three of 59 (5% [1-14%]) patients, all within the placebo group. Topical imiquimod treatment was well tolerated, and no high-grade side effects were observed.
Conclusion:
Topical imiquimod is an efficacious and feasible treatment for patients with CIN 2-3.
